REXAHN ANNOUNCES $35 MILLION KOREAN INVESTMENT

A A

Rexahn, a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer and disorders of the central nervous system, announced today that it has executed definitive agreements with Future Systems, Inc. (FSI), a Korean stock exchange (KOSDAQ) listed information technology company based in Seoul, Korea, which will be expanding its business to the biopharmaceutical industry.

Webbolt (http://webbolt.ecnext.com/coms2/news_60668_MED)